What Is Recombinant Human Growth Hormone?

Recombinant human growth hormone (rhGH) is a lab-made version of the growth hormone your pituitary gland naturally produces. It is manufactured using genetically engineered bacteria that carry the human gene for growth hormone, yielding a protein that is structurally identical to the one your body makes on its own. Since its approval in the mid-1980s, rhGH has become the standard treatment for children and adults whose bodies do not produce enough growth hormone, and it has also been approved for several other conditions that cause short stature or metabolic dysfunction.

Why a Synthetic Version Was Needed

Before recombinant technology existed, the only source of human growth hormone was cadaveric pituitary glands. Donated glands were collected from the deceased, and the hormone was extracted and purified for injection into children with growth hormone deficiency. The supply was always limited, and the process was expensive, but a far more serious problem emerged in the early 1980s. Recipients of pituitary-derived growth hormone began developing Creutzfeldt-Jakob disease (CJD), a fatal brain disorder caused by misfolded proteins called prions. Contaminated batches of cadaveric hormone were responsible for hundreds of CJD deaths worldwide.¹ The identification of CJD in these patients accelerated the push to develop a synthetic alternative.²

In 1985, recombinant human growth hormone reached the market, and pituitary-derived preparations were pulled. Because the recombinant version is produced in bacteria rather than extracted from human tissue, it carries no risk of prion contamination. The supply is also essentially unlimited, which opened the door to treating a wider range of conditions beyond classic growth hormone deficiency.

How It Is Made

The production process starts with inserting the gene for human growth hormone into the DNA of Escherichia coli bacteria. When those bacteria grow in fermentation tanks, they read the human gene and churn out growth hormone protein. This is the same basic approach used to produce recombinant insulin and many other biologic medicines. The bacteria produce high levels of the hormone, though much of it initially clumps into insoluble aggregates inside the cells.³

Researchers have refined the conditions to minimize that clumping. Growing the bacteria at lower temperatures, for instance, dramatically improves the amount of soluble, usable protein. One set of optimized conditions achieved up to 95% soluble growth hormone and, after multiple purification steps, yielded product that was over 97% pure.⁴ The finished product is a 191-amino-acid protein that is chemically identical to the growth hormone your pituitary releases during sleep and exercise.

What Growth Hormone Does in the Body

Growth hormone affects nearly every tissue, but the liver is its primary target. When growth hormone binds to receptors on liver cells, it triggers the production of insulin-like growth factor 1 (IGF-1), a secondary hormone that drives much of the growth effect on bones, cartilage, and muscle. The liver signaling pathway relies heavily on a protein called STAT5, which switches on the genes that produce IGF-1.⁵

Beyond growth, the hormone has broad metabolic effects. Its most prominent action is increasing the breakdown of stored fat and raising free fatty acid levels in the blood. It also boosts protein synthesis and reduces protein breakdown in muscle, while decreasing amino acid oxidation in the liver. These protein-sparing effects become especially important during fasting or stress: without adequate growth hormone, protein loss and urea production roughly double.⁶ Growth hormone also influences glucose metabolism, generally pushing blood sugar levels upward and reducing insulin sensitivity, which is one reason doctors monitor glucose carefully during treatment.⁷

Treating Children With Growth Hormone Deficiency

The original and most straightforward use of rhGH is replacing the hormone in children whose pituitary glands do not make enough of it. These children grow slowly and, without treatment, end up well below the height expected for their family. Treatment typically involves daily subcutaneous injections, usually given at bedtime to mimic the body’s natural nighttime surge of growth hormone.

The response in the first year is usually dramatic. In a Belgian study of children with idiopathic growth hormone deficiency, rhGH roughly doubled the rate of height gain during the first year of treatment. By the time those children reached adulthood, the vast majority had caught up: about 87% reached a normal height, and 92% ended up within the range predicted by their parents’ heights.⁸ Children who were heavier at the start of treatment tended to grow faster in the first year, suggesting that nutritional status plays a role in how well the body responds.⁹

Beyond height, treatment appears to carry psychological benefits. Short prepubertal children receiving rhGH showed improvements in behavior, self-esteem, and mood within the first three months, and those gains held steady through at least two years. Greater height gain and older age at the start of treatment were associated with larger psychological improvements.¹⁰

Uses Beyond Classic Deficiency

Regulatory agencies have approved rhGH for a number of conditions where children are short for reasons other than a straightforward lack of growth hormone. Two of the most important are Turner syndrome and Prader-Willi syndrome.

Turner syndrome affects girls who are missing part or all of one X chromosome. Without treatment, average adult height is typically well under 150 cm. A meta-analysis of controlled trials found that rhGH therapy increased final adult height by about 7 cm compared to untreated controls.¹¹ Individual results vary considerably, but starting treatment at a younger age tends to produce better outcomes. One study found treated girls reached about 152 cm on average, compared to about 144 cm in untreated controls, a meaningful gain that brings many patients closer to the normal adult range.¹² Adding the anabolic steroid oxandrolone to rhGH may further increase final height by a couple of additional centimeters compared to rhGH alone.¹¹

Prader-Willi syndrome is a genetic condition that causes poor muscle tone, short stature, and an overwhelming drive to eat. Growth hormone therapy in these children improves body composition and muscle strength. A lingering worry has been whether rhGH could worsen sleep-disordered breathing, which is already common in Prader-Willi syndrome. Several studies have addressed this directly. A six-month trial in prepubertal children with Prader-Willi found that the breathing disturbance index did not significantly change with treatment.¹³ A more recent study looking at a specific measure of breathing instability during sleep found no change attributable to growth hormone, though about one in five children did develop obstructive sleep apnea after starting treatment, which may relate to tonsillar enlargement rather than the drug itself.¹⁴ The consensus is that rhGH does not inherently cause sleep apnea in these children, but close monitoring is still recommended, especially during respiratory infections.¹⁵

Growth Hormone Replacement in Adults

Adults can also be growth hormone deficient, either because they had childhood deficiency that persisted or because of pituitary damage from a tumor, surgery, or radiation. In adults, the issue is not height but rather body composition and metabolic health. Adults with untreated growth hormone deficiency tend to accumulate excess body fat, especially around the abdomen, while losing lean muscle mass. They also show markers of increased cardiovascular risk, including higher levels of the inflammatory marker C-reactive protein and greater abdominal fat deposits.¹⁶

Replacing growth hormone reverses many of these changes. In one of the earliest controlled trials, adults with growth hormone deficiency who received rhGH for six months gained an average of about 5.5 kg of lean mass while losing about 5.7 kg of fat, even though their total body weight barely changed. Their basal metabolic rate also rose, and fasting cholesterol levels dropped.¹⁷ Longer-term studies confirmed that the favorable shift in lean mass and fat mass was sustained over at least three years of treatment.¹⁸

Safety Profile and Known Risks

Decades of surveillance data have painted a reassuring picture for most patients, but rhGH is not risk-free. The most commonly discussed concerns involve fluid retention, joint pain, and carpal tunnel-like symptoms, especially in adults who are dose-sensitive. These tend to resolve with dose adjustments.

A rarer but more serious side effect is intracranial hypertension, which is increased pressure inside the skull. According to data from a large international surveillance registry, the rate in children with idiopathic growth hormone deficiency was about 13 per 100,000 treatment-years. The risk was higher in certain groups: children with chronic kidney failure had the highest incidence at about 130 per 100,000 treatment-years, followed by those with Prader-Willi syndrome and Turner syndrome.¹⁹ Symptoms include headaches, visual changes, and nausea. The condition usually resolves when the dose is reduced or temporarily stopped.

The question that has hung over rhGH therapy for the longest is cancer risk. Growth hormone and IGF-1 promote cell growth, which raises a theoretical concern about fueling tumors. Large surveillance studies, however, have not found an increased rate of new cancers in children without pre-existing risk factors. In one major analysis, the number of new malignancies observed was essentially what you would expect in the general population of the same age.²⁰ The important caveat is that patients who had prior cancers treated with radiation did show a higher rate of second tumors, consistent with the known effects of radiation rather than growth hormone itself. Cancer risk in adults receiving long-term rhGH has also been monitored carefully, and reviews of the data have continued to look at the issue without finding clear evidence of increased risk in patients who do not already have risk factors.²¹

Misuse in Sports and Anti-Aging

Growth hormone has a reputation in popular culture as a performance enhancer and anti-aging elixir, but the evidence behind those uses is surprisingly thin. Athletes who use rhGH without a medical need are hoping for faster recovery, more muscle, and less fat. And while growth hormone does increase lean body mass, that does not necessarily translate into greater strength or better athletic performance. A systematic review of the available evidence concluded that claims about performance enhancement are not supported by the scientific literature, and that growth hormone may actually worsen exercise capacity while increasing side effects.²²

The distinction is important: replacing a genuine deficiency to restore normal physiology is very different from pushing levels far above normal in a healthy person. When the goal is supraphysiologic levels, the benefits are largely unproven while the risks, including fluid retention, joint pain, insulin resistance, and potential cardiac effects, are real.²³ Growth hormone is also widely used off-label in attempts to slow aging, though regulatory agencies have not approved it for that purpose, and the evidence that it meaningfully extends healthspan is lacking.²⁴

Detection in competitive sports has improved. Current anti-doping programs use two main strategies: one that measures changes in the ratio of different growth hormone protein forms (the isoform test), and another that tracks biomarkers like IGF-1 and a collagen breakdown product called P-III-NP. Longitudinal profiling of these biomarkers in individual athletes, an approach borrowed from the athlete biological passport concept, has shown promising ability to flag doping even outside the narrow detection window of older single-sample tests.²⁵

Weekly Formulations Are Changing the Treatment Experience

For decades, rhGH therapy has meant a daily injection, which is a significant burden for children and families. Several pharmaceutical companies have developed long-acting formulations that require only one injection per week. These work by modifying the growth hormone molecule or attaching it to carriers that slow its release into the bloodstream.

Clinical trials of weekly formulations have shown results that match or exceed daily injections. In a phase 2 trial of somapacitan (a modified growth hormone), the highest-dose weekly group achieved faster growth than the daily injection group, with gains sustained at one year.²⁶ A separate phase 3 trial of somatrogon, another weekly formulation, confirmed that once-weekly dosing was noninferior to daily treatment, with children in the weekly group growing at about 10.1 cm per year versus about 9.8 cm per year in the daily group at 12 months.²⁷ Fewer needlesticks per month is a real quality-of-life improvement, especially for young children who dread injections.

Cost and Access Barriers

One of the most persistent challenges with rhGH is its price. Treatment for a growing child can cost tens of thousands of dollars per year, and it often continues for years until growth plates close. Even when doctors recommend treatment, insurance coverage is not guaranteed. A study of physician referral patterns found that among children recommended for growth hormone therapy due to deficiency, Turner syndrome, or renal failure, roughly 28% were denied coverage by their insurers.²⁸ That study dates to the late 1990s, and the insurance landscape has evolved since then, but cost remains a barrier in many countries and health systems. Biosimilar versions of rhGH have begun to reach the market, which should eventually put downward pressure on prices, though uptake varies by region.

Recombinant Growth Hormone in Agriculture

The same recombinant DNA technology that produced human growth hormone was adapted to make bovine somatotropin (rbST), a version of the hormone used in dairy cattle to increase milk production. While rbST is a different protein than the human form, the manufacturing principle is the same. Administering rbST to cows modestly shifts the fat composition of their milk, lowering saturated fatty acids and raising monounsaturated fatty acids, while also reducing a measure of the fat’s potential to contribute to arterial plaque.²⁹ The use of rbST in dairy farming remains contentious and is banned in the European Union and Canada, though it is approved in the United States. It is worth noting that rbST has no direct relevance to human growth hormone therapy: they are different molecules used in entirely different contexts, but public confusion between the two sometimes fuels unfounded fears about recombinant hormones in general.